Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Aug;120(4):314-317.

Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer

Beth Gustafson  1 , Lindsey Douglass  1 , Timothy Pluard  1 , Janakiraman Subramanian  2
Affiliations

Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer

Beth Gustafson et al. Mo Med. 2023 Jul-Aug.

Abstract

Next-generation sequencing (NGS) identifies biomarkers with prognostic and predictive importance in patients with cancer. The enormous amounts of data generated by comprehensive NGS adds complexity to the identification of valid drug therapy targets. Rapid progress made in targeted drug development creates the need for novel methods to access these treatments for patients. Molecular tumor boards (MTB) not only aid in identifying targetable gene mutations by carefully reviewing NGS data, they can also take lead in creating patient access to the appropriate targeted therapy. Here we describe two patients with Kirsten Rat Sarcoma (KRAS) G12C mutation positive lung adenocarcinoma for whom MTB was able to procure AMG510 or sotorasib, a covalent KRAS G12C inhibitor, by expanded access program ahead of FDA approval.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tumor response to treatment with sotorasib in patient case 2.
None
See this image and copyright information in PMC

References

    1. Ostrem J, Peters U, Sos M, et al. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551. doi: 10.1038/nature12796. - DOI - PMC - PubMed
    1. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17–33. doi: 10.1016/j.cell.2017.06.009. - DOI - PMC - PubMed
    1. Hong D, Fakih M, Strickler J, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–1217. doi: 10.1056/NEJMoa1917239. - DOI - PMC - PubMed
    1. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217–223. doi: 10.1038/s41586-019-1694-1. - DOI - PubMed
    1. Nipp RD, Hong K, Paskett ED. Overcoming Barriers to Clinical Trial Enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105–114. doi: 10.1200/EDBK_243729. - DOI - PubMed